Vericiguat on C-reactive Protein Level and Prognosis in Patients with Hypertensive Heart Failure
High Blood Pressure & Cardiovascular Prevention · 22.08.2024 · 31 (5) · 485-492
DOI: 10.1007/s40292-024-00664-y ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift High Blood Pressure & Cardiovascular Prevention, online erschienen am 22.08.2024. Verfasst von Yabing Cao und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department 1 of Cardiology, Xingtai Third Hospital, Xingtai, Hebei Province, 054000, China. Hauptthemen laut MEDLINE: Heart Failure, C-Reactive Protein, Biomarkers, Ventricular Function, Left. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 35 Literaturangaben.
Themen: Herzinsuffizienz
Abstract (Originalsprache)
INTRODUCTION: Hypertensive heart failure (HHF) has a high incidence and poor prognosis. AIM: This article evaluated the efficacy and safety of Vericiguat in HHF and analyzed the relationship between C-reactive protein (CRP) levels and patient prognosis. METHODS: 110 HHF patients were divided into Placebo and Vericiguat groups. Cardiac function was assessed by echocardiography and 6-minute walk test (6MWT). Blood samples were collected to detect the levels of N-terminal pro-brain natriuretic peptide (NT-proBNP), cardiac troponin I (cTnI), endothelin (ET-1), nitric oxide (NO), and CRP. RESULTS: Left ventricular end systolic diameter (LVESD) and left ventricular end diastolic dimension (LVEDD) were reduced, the left ventricular ejection fraction (LVEF) and 6MWT were increased, and the serum levels of NT-proBNP, cTnI, ET-1, NO, and CRP were decreased in Vericiguat group as against Placebo group; The total effective rate was 76.4% in Placebo group and 92.7% in Vericiguat group (P 0.05). The proportion of persons with poor prognosis and no improvement of cardiac function in patients with highly expressed CRP before treatment was higher as against patients with low expression of CRP (P < 0.05). Highly expressed CRP is an independent risk factor for poor prognosis. CONCLUSION: Vericiguat is safe and effective in improving cardiac function in HHF patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department 1 of Cardiology, Xingtai Third Hospital, Xingtai, Hebei Province, 054000, China.
- Department 2 of Cardiology, Xingtai Third Hospital, Xingtai, Hebei Province, 054000, China.
- Department of Cardiovascular Intensive Care Unit, Xingtai Third Hospital, Xingtai, Hebei Province, 054000, China.
- Department of Cardiology, Xingtai Third Hospital, Xingtai, Hebei Province, 054000, China.
- Department 1 of Cardiology, Xingtai Third Hospital, Xingtai, Hebei Province, 054000, China. lianshao471777@163.com.
Zitieren
APA
Cao, Y., Sun, Y., Miao, B., Zhang, X., Zhao, Q., Qi, L., Chen, Y., & Zhu, L. (2024). Vericiguat on C-reactive Protein Level and Prognosis in Patients with Hypertensive Heart Failure. High Blood Pressure & Cardiovascular Prevention, 31(5), 485-492. https://doi.org/10.1007/s40292-024-00664-y
Vancouver
Cao Y, Sun Y, Miao B, Zhang X, Zhao Q, Qi L, et al. Vericiguat on C-reactive Protein Level and Prognosis in Patients with Hypertensive Heart Failure. High Blood Pressure & Cardiovascular Prevention. 2024;31(5):485-492. doi:10.1007/s40292-024-00664-y
BibTeX
@article{Cao2024,
author = {Cao, Yabing and Sun, Yunjing and Miao, Bo and Zhang, Xiao and Zhao, Qingzhou and Qi, Liping and Chen, Yaoqi and Zhu, Lingling},
title = {Vericiguat on C-reactive Protein Level and Prognosis in Patients with Hypertensive Heart Failure},
journal = {High Blood Pressure & Cardiovascular Prevention},
year = {2024},
volume = {31},
number = {5},
pages = {485--492},
doi = {10.1007/s40292-024-00664-y}
}
EUVIMED